Key highlights
- Achieved 68% reduction in the risk of recurrence compared to the control arm (Hazard Ratio 0.32)
- Met primary endpoint in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer
- Reported zero Grade 3 or higher treatment-related adverse events or discontinuations
- Planned BLA submission for BCG-unresponsive NMIBC scheduled for March 2027
- Anticipated second BLA filing for intermediate-risk and high-grade Ta NMIBC in Q2 2027
Clinical Outcomes and Safety Profile
CG Oncology announced that its PIVOT-006 Phase 3 registrational trial achieved its primary endpoint, showing a 68% reduction in the risk of recurrence for patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer. The study, which evaluated adjuvant intravesical cretostimogene grenadenorepvec following complete tumor resection, demonstrated a hazard ratio of 0.32 with high statistical significance. Safety data remained consistent with previous studies, as the trial reported no Grade 3 or higher treatment-related adverse events and no discontinuations due to treatment-related issues during the median follow-up period of 17 months.
Regulatory Timeline and Strategy
The company is concurrently advancing its regulatory strategy, with plans to submit a Biologics License Application for cretostimogene in BCG-unresponsive NMIBC by March 2027. This submission will now include both patients with carcinoma in situ and those with high-grade papillary-only disease, effectively covering the full range of BCG-unresponsive cases. Additionally, a second BLA submission specifically for the intermediate-risk and high-grade Ta NMIBC population targeted in the PIVOT-006 trial is anticipated in the second quarter of 2027, following the completion of all necessary manufacturing activities supporting both regulatory filings.
Execution Milestone
“The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase 3 trial in intermediate-risk and HG Ta NMIBC.”
Business Overview and Market Opportunity
CG Oncology operates as a late-stage clinical biopharmaceutical company specializing in the development of oncolytic immunotherapies. Its lead candidate, cretostimogene, is an investigational oncolytic virus designed to selectively replicate in cancer cells and trigger an anti-tumor immune response. The company focus on NMIBC addresses a significant unmet need in the urology market, particularly for the estimated 50,000 patients in the United States who currently have no FDA-approved adjuvant treatment options for intermediate-risk and high-grade Ta disease, representing a substantial potential market expansion if the drug receives regulatory approval.
Financial and Technical Context
Following the clinical update, CG Oncology shares rose 6.06% to $74.40, resulting in a market capitalization of approximately $6.65 billion. The stock has demonstrated strong performance with a 20.31% gain over the last month, supported by a Relative Strength Index of 61.3. While the company is currently in the pre-commercial stage with annual revenue of $4.04 million, it maintains a robust pipeline focused on intravesical therapies. The successful Phase 3 data and defined BLA submission schedule provide a clear path toward commercial transition within the high-growth biotechnology sector.
Up 14.0% since our story on 16 Nov: $74.40 when we broke it → $84.78 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $59.96 |
|---|---|
| 20 Oct | $61.93 |
| 21 Oct | $62.24 |
| 22 Oct | $62.54 |
| 23 Oct | $61.71 |
| 26 Oct | $61.56 |
| 27 Oct | $62.94 |
| 28 Oct | $63.96 |
| 29 Oct | $63.47 |
| 30 Oct | $64.68 |
| 2 Nov | $61.96 |
| 3 Nov | $64.06 |
| 4 Nov | $67.71 |
| 5 Nov | $64.80 |
| 6 Nov | $75.99 |
| 9 Nov | $74.74 |
| 10 Nov | $72.64 |
| 11 Nov | $72.61 |
| 12 Nov | $70.15 |
| 13 Nov | $74.40 |
| 16 Nov | $84.78 |
Management commentary
“Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported.”
| Share price | $74.40 |
|---|---|
| Market cap | $6.6B |
| Revenue (annual) | $4M |
| 1-month price change | +20.31% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by CG Oncology, Inc. announcing topline results from the PIVOT-006 Phase 3 trial.
Track CG Oncology, Inc. live
Get the next CG Oncology, Inc. SEC filing seconds after it lands.



